Lineage Cell Therapeutics's revenue for the
three
months ended in Dec. 2023 was $2.09 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $8.95 Mil.
Lineage Cell Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05.
Warning Sign:
Lineage Cell Therapeutics Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Lineage Cell Therapeutics was -40.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 118.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 57.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Lineage Cell Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 118.30% per year. The lowest was -51.60% per year. And the median was -6.10% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lineage Cell Therapeutics's Revenue
For the Biotechnology subindustry, Lineage Cell Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Revenue falls into.
Lineage Cell Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Lineage Cell Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Lineage Cell Therapeutics (Lineage Cell Therapeutics) Business Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LCTX has been successfully added to your 